Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL392801 | 0.86 | MGLL (0.68) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL2322628 | 0.82 | MGLL (0.64) | MGLLMEN1KMT2ALMNATP53 | |
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL6220062 | 0.82 | MGLL (0.64) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL4671500 | 0.81 | HSD11B1 (0.58) | MGLLHSD11B1 | |
| SCHEMBL4670951 | 0.81 | KMT2A (0.62) | MGLLMEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL4673866 | 0.81 | MGLL (0.51) | MGLLMEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL654047 | 0.81 | HTR2A (0.49) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL196518 | 0.81 | SRD5A2 (0.62) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL13657578 | 0.80 | MGLL (0.71) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL4671408 | 0.80 | MGLL (0.49) | MGLLMEN1KMT2ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1091957-B1 | PYRIMIDIN-AMINOMETHYL-PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE CONTROL OF HELICOBACTER BACTERIA | ALTANA PHARMA AG (DE) | 2004-12-15 | — | — | EP | disclosed |
| EP-0772593-B1 | THIOPYRIDYL COMPOUNDS FOR CONTROLLING HELICOBACTER BACTERIA | ALTANA PHARMA AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-6479514-B1 | FOR THE CONTROL OF HELICOBACTER BACTERIA IN INFECTED PATIENTS | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | disclosed |
| WO-1999061439-A1 | PYRIMIDIN-AMINOMETHYL-PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE CONTROL OF HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-02 | — | — | WO | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| EP-0863899-A1 | PYRIDOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| WO-1997019946-A1 | PYRIDOPYRIMIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| EP-0772593-A1 | THIOPYRIDYL COMPOUNDS FOR CONTROLLING HELICOBACTER BACTERIA | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1997-05-14 | — | — | EP | disclosed |
| EP-0731801-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996002505-A1 | THIOPYRIDYL COMPOUNDS FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996000224-A1 | 4-S- AND N-SUBSTITUTED 6-ALKYLPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995015324-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | MGLL 2851/4885MEN1 3476/4885KMT2A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.